Tejara Capital’s Indivior Pharmaceuticals INDV Stock Holding History

Tejara Capital’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-112,400	Closed	-$3.43M	–	78
2026 Q1	$3.43M	Buy	+112,400	New	+$3.71M	1.13%	32
2025 Q3	–	Sell	-96,725	Closed	-$1.43M	–	64
2025 Q2	$1.43M	Sell	96,725 -24,675	-20%	-$287K	0.66%	44
2025 Q1	$1.16M	Buy	+121,400	New	+$1.28M	0.45%	52

Other funds holding INDV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Tejara Capital's INDV Position: Q2 2026 in Review

Tejara Capital sold out of Indivior Pharmaceuticals (INDV) in Q2 2026, closing a stake of 112,400 shares — an estimated $3.43M sold.

Tejara Capital first reported a position in INDV in Q1 2025 and held it in 3 quarters. The position peaked at $3.43M in Q1 2026. 336 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

Tejara Capital reported no remaining Indivior Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Tejara Capital sold 112,400 Indivior Pharmaceuticals shares in Q2 2026, an estimated $3.43M.
Tejara Capital first reported a position in Indivior Pharmaceuticals in Q1 2025 and held it in 3 quarters.
Tejara Capital's Indivior Pharmaceuticals position peaked at $3.43M in Q1 2026.
336 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Tejara Capital's 13F filing for Q2 2026, filed 11 Aug 2026.